Company Description

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.

The company was founded in 2004 and is headquartered in Durham, North Carolina.

Humacyte, Inc.

Country	United States
Founded	2004
Industry	Biotechnology
Sector	Healthcare
Employees	220
CEO	Laura Niklason

Contact Details

Address: 2525 East North Carolina Highway 54 Durham, North Carolina 27713 United States
Phone	919-313-9633
Website	humacyte.com

Stock Details

Ticker Symbol	HUMAW
Exchange	NASDAQ
Stock Type	Warrants
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001818382
CUSIP Number	44486Q111
ISIN Number	US44486Q1114

Key Executives

Name	Position
Dr. Laura E. Niklason M.D., Ph.D.	Founder, President, Chief Executive Officer and Director
Dale A. Sander	Chief Financial Officer, Chief Corporate Development Officer and Treasurer
Dr. Heather Ledbetter Prichard Ph.D.	Chief Operating Officer
Sabrina Osborne GPHR, SPHR	Chief People Officer
William John Scheessele	Chief Commercial Officer
Dr. Shamik J. Parikh M.D.	Chief Medical Officer
Dr. Yang Cao M.D., Ph.D.	Chief Regulatory Officer